Moreover, the SRXN1 overexpression brought HCC patients who infected with hepatitis B worse outcome in the training cohort, and the consistent phenomenon was observed in patients of the validation cohort (Figure 6B and F). This evidence concerns the gene SRXN1 and hepatocellular carcinoma.